Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

A study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on individuals with Pancreatic Ductal Adenocarcinoma, which is a type of cancer that begins in the ducts of the pancreas. The research specifically involves patients who have undergone surgical removal of the tumor, known as resected cancer, and have already finished neoadjuvant or adjuvant chemotherapy. Neoadjuvant refers to treatment given before surgery to shrink a tumor, while adjuvant refers to treatment given after surgery to help remove any remaining cancer cells.

The purpose of this study is to compare the effectiveness of a new drug called daraxonrasib, also known by its code name RMC-6236, against the current standard of care, which involves close observation by medical professionals. Daraxonrasib is an oral medication taken in the form of a tablet.

During the study, participants are assigned to one of two groups through a process called randomization. One group will receive the experimental drug, while the other group will receive the standard observation. The course of the study involves monitoring patients over time to see how long they remain free from the disease and to track overall survival.

The research process

The trial runs in 3 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Study assignment

    You will be assigned to one of two groups through a process called randomization, which is a way of assigning participants to different groups by chance.

    One group will receive the test medication, while the other group will follow the standard of care observation, which means monitoring your health without the specific test drug.

  2. Step 2

    Treatment phase

    If assigned to the treatment group, you will take daraxonrasib.

    This medication is provided as a 300 mg tablet and is taken by mouth.

  3. Step 3

    Monitoring and follow-up

    During the study, the focus is on disease-free survival, which is the time from the start of the assignment until the cancer returns or death occurs from any cause.

    The recurrence, or return of the cancer, is checked using specific medical imaging and evaluation rules.

    The study also monitors overall survival, which is the time from the start of the assignment until death from any cause.

    Health is monitored to check the safety and tolerability of the medication, including any side effects, changes in vital signs, physical ability to perform daily activities, and blood test results.

    The concentration of the medicine in the blood, known as pharmacokinetics, is also monitored.

Who can join the trial?

9 criteria

  • You must be at least 18 years old and agree to participate in the study by signing a consent form.
  • You must have an ECOG performance status of 0 or 1, which means you are able to carry out most daily activities and are physically active.
  • You must have a confirmed diagnosis of pancreatic ductal adenocarcinoma (a type of pancreatic cancer) that has been surgically removed.
  • The surgery must have been performed with curative intent (meaning the goal was to remove all cancer) and there must be no signs that the cancer has returned or spread to other parts of the body.
  • You must have received perioperative chemotherapy, which is medicine used to treat cancer either before or after surgery.
  • Your most recent round of cancer treatment must have ended within the last 12 weeks.
  • You must have adequate organ function, meaning your bone marrow (the part of your body that makes blood cells), liver, kidneys, and coagulation (your blood's ability to clot) are all working well.
  • You must have a documented RAS mutation status, which is a test result showing if there are specific changes in the genes that control how cells grow.
  • You must be able to swallow and take oral medications (pills or liquids taken by mouth).

Who cannot join the trial?

4 criteria

  • You have previously used a treatment that specifically targets RAS, which is a type of protein in the body that helps cells grow.
  • You have any health conditions that might prevent your body from being able to take or absorb the study medication properly.
  • You have had any major surgery within the 28 days before being assigned to a treatment group.
  • You are unable or do not wish to follow the study protocol, which is the set of rules and specific steps required for the clinical trial, including attending all scheduled visits and procedures.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Daraxonrasib is an experimental oral medication being tested to see if it can help prevent the cancer from returning in patients who have had surgery to remove pancreatic cancer after completing chemotherapy.

What is already known about the treatment

Daraxonrasib - This medication is taken as a tablet by mouth and is currently being studied in late-stage clinical trials to treat patients who have had surgery for pancreatic cancer. It belongs to a group of drugs known as RAS inhibitors, which work by specifically targeting and blocking certain mutated proteins that help cancer cells grow and multiply. By shutting down these molecular signals, the drug aims to prevent the cancer from returning after initial treatment.

Investigated diseases

Pancreatic ductal adenocarcinoma - This is a type of cancer that starts in the narrow tubes, called ducts, which carry digestive juices through the pancreas. The disease typically begins in the cells lining these ducts and can grow uncontrollably. As it progresses, the abnormal cells may form a mass and spread to nearby tissues or other parts of the body. In cases where the tumor has been surgically removed, the disease may still reappear in the same location or elsewhere.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2025-523495-23-00Protocol codeRMC-6236-304Estimated enrolment500 patientsSponsorRevolution Medicines Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).